Authors: Siu-Caldera, ML Rao, DS Astecker, N Weiskopf, A Vouros, P Konno, K Fujishima, T Takayama, H Peleg, S Reddy, GS

Citation: Ml. Siu-caldera et al., Tissue specific metabolism of 1 alpha,25-dihydroxy-20-epi-vitamin D-3 intonew metabolites with significant biological activity: Studies in rat osteosarcoma cells (UMR 106 and ROS 17/2.8), J CELL BIOC, 82(4), 2001, pp. 599-609

Authors: Reddy, GS Rao, DS Siu-Caldera, ML Astecker, N Weiskopf, A Vouros, P Sasso, GJ Manchand, PS Uskokovic, MR

Citation: Gs. Reddy et al., 1 alpha,25-dihydroxy-16-ene-23-yne-vitamin D-3 and 1 alpha,25-dihydroxy-16-ene-23-yne-20-epi-vitamin D-3: Analogs of 1 alpha,25-dihydroxyvitamin D-3 that resist metabolism through the C-24 oxidation pathway are metabolized through the C-3 epimerization pathway, ARCH BIOCH, 383(2), 2000, pp. 197-205

Authors: Siu-Caldera, ML Sekimoto, H Weiskopf, A Vouros, P Muralidharan, KR Okamura, WH Bishop, J Norman, AW Uskokovic, MR Schuster, I Reddy, GS

Citation: Ml. Siu-caldera et al., Production of 1 alpha,25-dihydroxy-3-epi-vitamin D-3 in two rat osteosarcoma cell lines (UMR 106 and ROS 17/2.8): Existence of the C-3 epimerization pathway in ROS 17/2.8 cells in which the C-24 oxidation pathway is not expressed, BONE, 24(5), 1999, pp. 457-463

Authors: Siu-Caldera, ML Sekimoto, H Peleg, S Nguyen, C Kissmeyer, AM Binderup, L Weiskopf, A Vouros, P Uskokovic, MR Reddy, GS

Citation: Ml. Siu-caldera et al., Enhanced biological activity of 1 alpha,25-dihydroxy-20-epi-vitamin D-3, the C-20 epimer of 1 alpha,25-dihydroxyvitamin D-3, is in part due to its metabolism into stable intermediary metabolites with significant biological activity, J STEROID B, 71(3-4), 1999, pp. 111-121

Authors: Sekimoto, H Siu-Caldera, ML Weiskopf, A Vouros, P Muralidharan, KR Okamura, WH Uskokovic, MR Reddy, GS

Citation: H. Sekimoto et al., 1 alpha,25-dihydroxy-3-epi-vitamin D-3: In vivo metabolite of 1 alpha,25-dihydroxyvitamin D-3 in rats, FEBS LETTER, 448(2-3), 1999, pp. 278-282